Nanjing Leads Biolabs Co., Ltd. (09887) at a glance
Code
09887
Company
Nanjing Leads Biolabs Co., Ltd.
Local name
LEADS BIOLABS-B
Market
Hong Kong Stock Exchange (H-share)
Share price
HK$37.46 -1.30 (-3.35%)Nov 12 close
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Nanjing Leads Biolabs Co., Ltd. (09887) Stock Price History
Nanjing Leads Biolabs Co., Ltd. closed at HK$37.46 on Nov 12, 2026, −17.9% over 1 month, −34.7% over 1 year.
Price5-day MA25-day MAHang Seng IndexDisclosures
1-Month HighHK$45.62Oct 12
1-Month LowHK$34.10Nov 3
1-Week Change−1.8%vs Nov 5
1-Month Change−17.9%vs Oct 12
If you had invested HK$10,000 1 month ago, it would be worth HK$8,211 today (−17.9%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −1.1%, while this stock moved −17.9%.
Last 10 Trading Days
Date
Close
Change
% Change
Nov 12 (Thu)
HK$37.46
−1.30
−3.35%
Nov 11 (Wed)
HK$38.76
−0.32
−0.82%
Nov 10 (Tue)
HK$39.08
+1.40
+3.72%
Nov 9 (Mon)
HK$37.68
+1.12
+3.06%
Nov 6 (Fri)
HK$36.56
−1.60
−4.19%
Nov 5 (Thu)
HK$38.16
+1.68
+4.61%
Nov 4 (Wed)
HK$36.48
+2.38
+6.98%
Nov 3 (Tue)
HK$34.10
−1.12
−3.18%
Nov 2 (Mon)
HK$35.22
−0.78
−2.17%
Oct 30 (Fri)
HK$36.00
−0.98
−2.65%
Price5-day MA25-day MAHang Seng IndexDisclosures
3-Month HighHK$76.10Aug 20
3-Month LowHK$34.10Nov 3
1-Month Change−17.9%vs Oct 12
3-Month Change−43.6%vs Aug 12
If you had invested HK$10,000 3 months ago, it would be worth HK$5,637 today (−43.6%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −5.6%, while this stock moved −43.6%.
Last 10 Trading Days
Date
Close
Change
% Change
Nov 12 (Thu)
HK$37.46
−1.30
−3.35%
Nov 11 (Wed)
HK$38.76
−0.32
−0.82%
Nov 10 (Tue)
HK$39.08
+1.40
+3.72%
Nov 9 (Mon)
HK$37.68
+1.12
+3.06%
Nov 6 (Fri)
HK$36.56
−1.60
−4.19%
Nov 5 (Thu)
HK$38.16
+1.68
+4.61%
Nov 4 (Wed)
HK$36.48
+2.38
+6.98%
Nov 3 (Tue)
HK$34.10
−1.12
−3.18%
Nov 2 (Mon)
HK$35.22
−0.78
−2.17%
Oct 30 (Fri)
HK$36.00
−0.98
−2.65%
Price25-day MA75-day MAHang Seng IndexDisclosures
6-Month HighHK$76.10Aug 20
6-Month LowHK$34.10Nov 3
3-Month Change−43.6%vs Aug 12
6-Month Change−50.3%vs May 12
If you had invested HK$10,000 6 months ago, it would be worth HK$4,968 today (−50.3%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −8.9%, while this stock moved −50.3%.
Monthly Closes
Month
Month-End Close
Monthly %
Nov 2026
HK$37.46
+4.1%
Oct 2026
HK$36.00
−30.8%
Sep 2026
HK$52.05
−28.0%
Aug 2026
HK$72.30
+35.4%
Jul 2026
HK$53.40
+8.3%
Jun 2026
HK$49.32
−19.5%
May 2026
HK$61.30
−23.4%
Price25-day MA75-day MAHang Seng IndexDisclosures
52-Week HighHK$93.95Apr 15
52-Week LowHK$34.10Nov 3
Year to Date−24.4%vs Dec 31
From 52-Week High−60.1%Apr 15
If you had invested HK$10,000 1 year ago, it would be worth HK$6,526 today (−34.7%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −10.8%, while this stock moved −34.7%.
Monthly Closes
Month
Month-End Close
Monthly %
Nov 2026
HK$37.46
+4.1%
Oct 2026
HK$36.00
−30.8%
Sep 2026
HK$52.05
−28.0%
Aug 2026
HK$72.30
+35.4%
Jul 2026
HK$53.40
+8.3%
Jun 2026
HK$49.32
−19.5%
May 2026
HK$61.30
−23.4%
Apr 2026
HK$80.00
+8.1%
Mar 2026
HK$74.00
+18.0%
Feb 2026
HK$62.70
−6.2%
Jan 2026
HK$66.85
+35.0%
Dec 2025
HK$49.52
−6.6%
Nov 2025
HK$53.00
−1.3%
Price13-week MA26-week MAHang Seng Index
3-Year HighHK$92.00Apr 10, 2026
3-Year LowHK$35.80Oct 23, 2026
Annualized Return−35.9%
Max Drawdown−61.1%
If you had invested HK$10,000 3 years ago, it would be worth HK$5,583 today (−44.2%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −5.4%, while this stock moved −44.2%.
Yearly Closes
Year
Year-End Close
Yearly %
2026 (YTD)
HK$37.46
−24.4%
2025
HK$49.52
―
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Jul 2025). Please check the latest prices before trading.
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No.11Disclosure2026/10/30 13:01
事業の状況
VOLUNTARY ANNOUNCEMENT PART B OF LBL-047 PHASE I STUDY COMPLETES FIRST DOSING OF A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS; NOVEL BDCA2/TACI DUAL-TARGETING DESIGN ENTERS CLINICAL EVALUATION IN PATIENTS
事業の状況
VOLUNTARY ANNOUNCEMENT PRESENTATION OF UPDATED CLINICAL AND TRANSLATIONAL DATA OF LBL-024 FOR EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, BILIARY TRACT CANCER AND COLORECTAL CANCER AT 2026 ESMO
事業の状況
VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) AS FIRST-LINE TREATMENT FOR GASTRIC CANCER PROGRESSES TO EXPANSION STAGE
事業の状況
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE IB/II CLINICAL TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION THERAPY FOR METASTATIC COLORECTAL CANCER
事業の状況
VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA FOR FIRST-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER
事業の状況
VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED EP-NEC SELECTED AS LBA AND THREE STUDIES SELECTED FOR PROFFERED PAPER PRESENTATIONS AT 2026 ESMO
事業の状況
VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC PRESENTED ORALLY AT WCLC 2026